Report cover image

Global Scopolamine Butylbromide Capsules Market Growth 2025-2031

Published Nov 18, 2025
Length 86 Pages
SKU # LPI20579750

Description

The global Scopolamine Butylbromide Capsules market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

Scopolamine Butylbromide Capsules, the indications are 1. It is used for the preoperative preparation of stomach, duodenum and colon endoscopy, endoscopic retrograde cholangiopancreatography, and the preoperative preparation of gas barium hypotonia or abdominal CT scan of stomach, duodenum and colon. Reduce or inhibit gastrointestinal motility; 2. It is used for gastrointestinal spasm, biliary colic, renal colic or hyperperistalsis of gastrointestinal tract caused by various etiologies.

United States market for Scopolamine Butylbromide Capsules is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Scopolamine Butylbromide Capsules is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Scopolamine Butylbromide Capsules is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Scopolamine Butylbromide Capsules players cover AdvaCare Pharma, Zuche Pharmaceuticals, SHRI HARI ENTERPRISE, Facmed Pharmaceuticals Private Limited, Guangzhou Baiyunshan Pharmaceutical Co.,Ltd, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LP Information, Inc. (LPI) ' newest research report, the “Scopolamine Butylbromide Capsules Industry Forecast” looks at past sales and reviews total world Scopolamine Butylbromide Capsules sales in 2024, providing a comprehensive analysis by region and market sector of projected Scopolamine Butylbromide Capsules sales for 2025 through 2031. With Scopolamine Butylbromide Capsules sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Scopolamine Butylbromide Capsules industry.

This Insight Report provides a comprehensive analysis of the global Scopolamine Butylbromide Capsules landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Scopolamine Butylbromide Capsules portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Scopolamine Butylbromide Capsules market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Scopolamine Butylbromide Capsules and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Scopolamine Butylbromide Capsules.

This report presents a comprehensive overview, market shares, and growth opportunities of Scopolamine Butylbromide Capsules market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
12 Pieces/Box
24 Pieces/Box

Segmentation by Application:
Gastrointestinal Spasm and Hypermotility
Biliary Colic
Renal Colic
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
AdvaCare Pharma
Zuche Pharmaceuticals
SHRI HARI ENTERPRISE
Facmed Pharmaceuticals Private Limited
Guangzhou Baiyunshan Pharmaceutical Co.,Ltd
Guangdong Huanan Pharmaceutical Group Co., Ltd
Lodays Pharmaceutical(Hubei) Co.,Ltd
Chengdu First Pharmaceutical Co., Ltd
Guangzhou Hanfang Modern Chinese Medicine Research and Development Co., Ltd

Key Questions Addressed in this Report

What is the 10-year outlook for the global Scopolamine Butylbromide Capsules market?

What factors are driving Scopolamine Butylbromide Capsules market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Scopolamine Butylbromide Capsules market opportunities vary by end market size?

How does Scopolamine Butylbromide Capsules break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.

Table of Contents

86 Pages
*This is a tentative TOC and the final deliverable is subject to change.*
1 Scope of the Report
2 Executive Summary
3 Global by Company
4 World Historic Review for Scopolamine Butylbromide Capsules by Geographic Region
5 Americas
6 APAC
7 Europe
8 Middle East & Africa
9 Market Drivers, Challenges and Trends
10 Manufacturing Cost Structure Analysis
11 Marketing, Distributors and Customer
12 World Forecast Review for Scopolamine Butylbromide Capsules by Geographic Region
13 Key Players Analysis
14 Research Findings and Conclusion
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.